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Abstract
Elevated plasma arginine vasopressin (AVP) levels have been found in
human hypertension subjects and several salt dependent experimental animal
models of hypertension including the Dahl salt sensitive hypertension (SSHTN)
model. The orexin system is involved in AVP regulation and its over activation
has been implicated in hypertension, however, the role of brain orexin in
SSHTN is unknown. We hypothesized that increased activity of orexin in the
paraventricular nucleus (PVN), a prominent region in AVP production,
contributes to SSHTN via enhancing AVP signaling. Eight-week-old male adult
Dahl salt sensitive (DS) and age and sex matched Sprague Dawley (SD) rats
were placed on either a high salt (HS, 8% NaCl) or normal salt (NS, 0.4% NaCl)
diet for 5 weeks. Five weeks HS intake did not increase mean arterial pressure
(MAP) or alter PVN mRNA expression of chronic neuronal activation marker
Fra1, orexin receptor 1 (OX1R), or orexin receptor 2 (OX2R) but increased
PVN AVP mRNA expression in SD rats. HS diet induced significant increases
in MAP and PVN mRNA levels of Fra1, AVP, OX1R, and prepro orexin in DS
rats. Intracerebroventricular (ICV) infusion of orexin A (0.2 nmol) increased
PVN AVP mRNA levels in SD rats. Incubation of cultured hypothalamus
neurons from newborn SD rats with orexin A resulted in increases in AVP
mRNA expression which were attenuated by OX1R blockade. In addition
increased cerebrospinal fluid (CSF) sodium concentration through ICV infusion
of NaCl salt solution (4µmol) increased PVN OX1R and AVP mRNA levels in
SD rats. Furthermore, bilateral PVN microinjection of the OX1R antagonist
SB408124 resulted in a greater reduction in MAP in HS intake (-16±5 mmHg)
compared to NS fed (-4±4 mmHg) anesthetized DS rats. These results suggest
that elevated PVN OX1R activation may be involved in SSHTN through
enhancing AVP signaling.
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Chapter 1. Introduction
1.1 Overview and Significance
High blood pressure or hypertension is highly prevalent (102) and
contributes significantly to both the incidence and mortality from cardiovascular
disease in particular ischemic heart disease and stroke (80). Since
cardiovascular disease is the leading global cause of death responsible for
more than 17 million deaths per year (102) the discovery of the causes of
hypertension are of great importance to society. It is well-established that
elevated salt intake is a primary contributor to essential hypertension (74, 108,
148, 149) and the majority of individuals with essential hypertension are salt
sensitive (148) meaning increased salt intake will increase blood pressure and
decreased salt intake will decrease blood pressure in these individuals.
Abnormalities in renal, vascular, hormonal, and neural responses to salt
contribute to the pathogenesis of salt sensitive hypertension (SSHTN) (74).
However, the cellular and molecular mechanisms that link elevated salt intake
and hypertension are not fully understood. Therefore, the discovery of new
mechanisms whereby salt contributes to hypertension may elucidate new
targets for future treatment.

1.2 Regulation of Arterial Blood Pressure
As the blood is pumped by the heart it exerts a force over a unit surface
area on the blood vessel walls that is termed blood pressure. With every single
heartbeat, pressure on the vessel walls oscillates from a high pressure when
the ventricles contract termed the systole portion of the heart cycle to a lower
pressure when the ventricles relax and refill termed the diastole portion of the
heart cycle. Therefore, when measured, usually at the brachial artery, blood
pressure is given as two numbers, the pressure at systole over the pressure at

The material contained in this chapter is in preparation for submission to a journal.
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diastole. At any point in time during a single heart cycle the pressure will be
somewhere in this range between the systole and diastole pressures. For
adult’s blood pressure should normally be <120/80 mmHg (14). Due to the
pumping action of the heart, a pressure difference between the arteries and
veins is created with pressure that is highest in the arteries and lowest in the
veins. This pressure difference causes blood to flow in the circulation (92).
Using the fundamental equation equivalent to Ohm’s law for circuits that relates
flow to resistance and pressure (∆Pressure=flow x resistance), and assuming
pressure at the end of venous system to be negligible, then the mean pressure
of the arterial side (MAP) of the systemic circulatory system can be calculated
by the product of cardiac output (CO) and total peripheral resistance (TPR)
(MAP=CO X TPR) (92). CO is further defined as the product of stroke volume
(SV) and heart rate (HR) (CO=SV X HR) (118). Arterial blood pressure is
regulated by two main systems, the kidneys regulation of blood volume and the
autonomic nervous system control over the kidneys, heart, and vasculature.
1.2.1 Short Term Blood Pressure Regulation
Acute regulation of blood pressure (minutes to hours) is regulated via the
baroreceptor reflex control of sympathetic nerve activity (SNA) (20).
Mechanoreceptors located in the carotid sinus and aortic arch have discharge
frequencies that depend on arterial pressure (112). Afferent signals are sent
from these mechanoreceptors via the carotid sinus nerve (a branch of cranial
nerve IX; glossopharyngeal) and aortic depressor nerve (a branch of cranial
nerve X; vagus) to the nucleus tractus solitarii (NTS) in the medulla (114, 136).
The NTS has excitatory projections to the caudal ventrolateral medulla (CVLM)
(117) and the CVLM has inhibitory projections to the rostral ventrolateral
medulla (RVLM) (114) which is the main nuclei responsible for tonic excitatory
drive to sympathetic preganglionic neurons in the intermediolateral cell column
(IML) of the spinal cord (54). When blood pressure is reduced the discharge
frequencies of the mechanoreceptors in the carotid sinus and aortic arch are
2

reduced and the inhibitory influence of the CVLM on the RVLM is decreased.
This results in an increase in sympathetic stimulation to the heart resulting in an
increase in HR and force of contraction which increases SV and thus CO,
increased sympathetic stimulation to blood vessels to increase vascular
resistance, and activation of renal sympathetic nerves innervating the
juxtaglomerular cells stimulating renin secretion and Ang II formation ultimately
resulting in elevated blood volume and CO. Collectively these actions result in a
compensatory increase in blood pressure (48). Alternatively, when blood
pressure is increased the inhibitory influence of the CVLM on the RVLM is
increased resulting in a decrease in sympathetic outflow to the heart,
vasculature, and kidneys to decrease blood pressure (48) (Figure 1.1).

Figure 1.1 Diagram of the arterial baroreceptor reflex control of short term
blood pressure regulation. Solid lines, excitatory; dashed line, inhibitory. (NTS)
nucleus tractus solitarii, (CVLM) caudal ventrolateral medulla, (RVLM) rostral
ventral lateral medulla, (SGN) sympathetic ganglionic neuron. Adapted from
Brooks and Osborn (9).
3

1.2.2 Long Term Blood Pressure Regulation
Long term (weeks to months) regulation of arterial pressure is
predominately regulated by the kidneys (57). The kidneys have the intrinsic
ability to excrete salt (natriuresis) and water (diuresis) in response to increased
perfusion pressure. Long term arterial pressure is set by the kidneys at a level
that is required to excrete a volume of water or amount of salt equivalent to
water or salt intake or in order to maintain sodium and water balance over an
extended period of time (56). If salt intake or water intake is greater than
excretion, extracellular fluid volume will increase which will increase blood
volume leading to an increase in cardiac output and increase arterial pressure.
In response to the increased pressure the kidneys will increase excretion of
salt/water to reduce extracellular fluid volume and ultimately arterial pressure
back to the equilibrium pressure were salt and water intake is equivalent to salt
and water excretion. If salt or water intake is less than excretion, arterial
pressure decreases and the kidneys decrease natriuresis /diuresis until arterial
pressure returns to the equilibrium pressure (55, 56) (Figure 1.2).

Figure 1.2 Diagram of the kidneys control of long term blood pressure
regulation. (BP) blood pressure, (ECF) extracellular fluid.
4

1.3 Body Fluid Homeostasis and Vasopressin
Body water is separated into two compartments; the extracellular fluid
(ECF) (which is comprised of interstitial fluid and plasma or intravascular fluid)
and intracellular fluid (ICF) (3). Dissolved in the body fluids are many different
salts including NaCl, KCl, and NaHCO3. Out of these NaCl is consumed in
greatest amounts and the cation Na+ is the major component of extracellular
fluid (3). Therefore, its quantity largely determines extracellular osmolality (the
concentration of all dissolved solutes in a solution) which determines
extracellular and intracellular fluid volume (143). Changes in salt intake thus
pose a common daily challenge to the maintenance of body fluid homeostasis
(maintaining osmolality of body fluids and intravascular blood volume).
When NaCl is ingested its ion components Na+ and Cl- are absorbed in
the small intestine and become evenly distributed in the plasma of the blood.
This results in an increase in ECF osmolality (143). Since sodium ions do not
easily cross the cell membrane they are confined to the ECF compartment.
However, water can cross the cell membrane and moves from a region of low
osmolality to high osmolality. Therefore, when sodium ions accumulate in the
ECF compartment water moves from the ICF compartment (low osmolality) to
the ECF compartment (high osmolality) were the fluid volume expands above
normal volume (143). Several physiological responses are then initiated to
restore sodium and water balance including increased thirst and release of
arginine vasopressin (AVP) the antidiuretic hormone which increases renal
reabsorption of water (3). Both compensatory responses dilute the extracellular
Na+ concentration back to normal. Natriuresis via the kidneys, is also increased
and the excess salt is eliminated in the urine and the ECF fluid volume naturally
returns to normal (3).
If sodium concentration in the extracellular compartment is reduced ECF
osmolality is reduced and water moves from the ECF compartment (low
osmolality) to the ECF compartment (high osmolality) were fluid volume
expands above normal (3). This results in a decrease of circulating sodium
concentration and reduced blood pressure. The kidneys increase the release of
5

renin which catalyzes the formation of angiotensin I from angiotensinogen. The
angiotensin converting enzyme catalyzes the reaction of angiotensin I to
angiotensin II. Angiotensin II causes vasoconstriction in order to increase blood
pressure and also stimulates the secretion of aldosterone from the adrenal
gland. Aldosterone causes sodium reabsorption by the kidneys in order to
prevent its loss in the urine (3). It has also been shown in animals that thirst
along with AVP secretion are also responses to sodium depletion (17, 63)
which supports that thirst and AVP secretion are additionally regulated by
volume dependent mechanisms.
1.3.1 Neural Circuitry Involved in Osmotic Regulation of Vasopressin
Release
AVP secretion is predominantly regulated by changes in blood osmolality
and to a lesser extent by a decrease in ECF volume (43). In particular E.B.
Verney was the first to show that only hypertonic solutions with solutes such as
NaCl that are impermeable to the cell membrane and create osmotic pressure
activate osmoreceptors that trigger thirst and AVP release (145). In this early
study E.B. Verney concluded these osmoreceptors responsible for the
regulation of AVP secretion were located in the brain. In a further study by
Jewell et al. the location was narrowed down to be in the anterior hypothalamic
area (67). It was latter suggested by two groups (95, 139) that these
osmoreceptors likely lied outside of the blood brain barrier since carotid artery
infusion of hyperosmolar solutions of NaCl, sucrose, or urea which do not pass
the blood brain barrier effectively withdrew water and dehydrated the brain
compartment however only hyperosmolar solutions of NaCl and sucrose which
do not easily cross the cell membrane stimulated AVP release and thirst. Since
urea easily penetrates the cell membrane it likely did not dehydrate and
activate the supposed osmoreceptors that were present outside the blood brain
barrier (95). Mckinley hypothesized the location of these osmoreceptors to be
the two circumventricular organs of the lamina terminalis region which is
located on the rostral wall of the 3rd ventricle that lack a blood brain barrier (95,
96). These circumventricular organs are called the organum vasculosum of the
6

lamina terminalis (OVLT) and the subfornical organ (SFO).
Most neurons in the brain are protected from changes in concentrations
of circulating ions and hormones in the plasma that organs and tissues are
usually exposed to by the presence of blood brain barrier that limits exchange
between plasma in brain blood capillaries and brain tissue. However, the SFO
and OVLT have a highly penetrable blood brain barrier due to fenestrated
capillaries therefore they are sensitive to changes in plasma osmolality and
circulating hormones (19). Another region of the lamina terminalis called the
median preoptic nucleus (MnPO) lies between the OVLT and SFO. Both the
SFO (82, 98) and OVLT (93) have direct excitatory projections to the
hypothalamic paraventricular nucleus (PVN) as well as indirect excitatory
projections to the PVN through projections to the MnPO (82, 98). The PVN is
composed of parvocellular and magnocellular neurons. Parvocellular neurons
have axon projections to the RVLM in the brainstem and IML in the spinal cord
which play significant roles in regulating SNA (13, 116). Magnocellular PVN
neurons synthesize AVP and transport it along nerve fibers that connect the
hypothalamus with the posterior lobe of the pituitary gland called the
neurohypophysis were it is stored and released (115).
The function of these circumventricular organs in the regulation of AVP
secretion has been supported by lesion studies. Separate lesions of the OVLT
and SFO and MNPO all attenuate osmotic stimulation of AVP release (86, 87,
94, 140). Total ablation of the lamina terminalis completely abolished osmotic
stimulation of AVP (96) demonstrating all three regions may be important in
osmotic stimulation of AVP release. In addition to these circumventricular
organs as the brain site for osmotic regulation of AVP release, evidence
suggests these regions are also responsible for angiontensin II regulation of
AVP release. Cutting SFO efferents was found to attenuate angiotensin II
induced stimulation of AVP release (73). It has also been shown that this region
displays high density of the angiotensin II type 1 receptor (97).
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1.3.2 Vasopressin Hemodynamics and Blood Pressure Control
Mechanisms
In addition to the role of AVP in body fluid homeostasis, AVP is involved
in blood pressure regulation. In normal conscious rats, dogs, and humans it has
been found that acute 30-60 minute intravenous infusions of AVP exerts a
significant dose dependent increase in MAP only at non physiological high
plasma concentrations that are higher than those required for antidiuresis (26).
However, it has also been found in rats, dogs, and humans that plasma AVP
exerts vasoconstrictor activity at lower physiological concentrations within the
range of maximum antidiuretic activity (26). The lack of a pressor response to
increased plasma AVP levels at lower physiological concentrations is due to its
action of decreasing cardiac output as acute 30-60 min Intravenous infusion of
AVP exerts a dose dependent decrease in cardiac output in rats, dogs, and
humans (26).
The ability of AVP to decrease cardiac output and buffer the pressor
response may be explained by AVP activating reflex decreases in SNA. It has
been shown that animals that have received baroreceptor denervation or where
the central nervous system was totally eliminated develop an increased blood
pressure response at lower amounts of intravenously administered AVP (22, 26,
110, 147). This enhancement of pressor sensitivity is greater than other
vasoconstrictor agents such as angiotensin II or norepinephrine (22, 26, 110,
147) which demonstrates AVP is one of the most powerful circulating
vasoconstrictors. One mechanism is the ability of circulating AVP to activate V1
receptors in the area postrema, which is another circumventricular organ
lacking a blood brain barrier, and augment baroreflex sympatho-inhibition (60).
Microinjection of AVP into the SFO decreased mean area under the curve
blood pressure but not heart rate in SD rats which was blocked by V1 receptor
blockade suggesting AVP may also activate V1 receptors in the SFO outside of
the baroreflex neural circuitry resulting in a decrease in SNA (135).
The known mechanisms that circulating AVP can increase blood
pressure include activation of V1A Gq/11 protein coupled receptors on vascular
8

smooth muscle cells causing contraction, inducing vasoconstriction and
increasing total peripheral resistance. The widely accepted calcium signaling
pathway for the V1A receptor on vascular smooth muscle cells involves
phospholipase C activation of IP3 (8, 106). When activated the alpha subunit
of the Gq/11 protein exchanges GDP for GTP and dissociates from the beta and
gamma subunits. The GTP bound alpha subunit binds and activates
phospholipase Cβ which causes the hydrolysis of P1P2 increasing levels of
DAG and IP3. IP3 binds the IP3R on the endoplasmic reticulum and stimulates
calcium release into the cell (8, 106) which causes contraction of the cell
(Figure 1.3). AVP may also act on the kidneys to increase water reabsorption
causing an increase in intravascular volume which will increase SV and
ultimately arterial pressure. This is mediated through activation of V2 Gs protein
coupled receptors on the basolateral membrane of the principle cells of the
kidney collecting duct (8). When activated the alpha subunit of the Gs protein
exchanges GDP for GTP and dissociates from the beta and gamma subunits.
The GTP bound alpha subunit binds and activates adenylate cyclase which
takes ATP and produces the second messenger cAMP. cAMP activates protein
kinase A which increases exocytosis and decreases endocytosis of aquaporin
water channel containing vesicles. This increases aquaporin 2 channels in the
apical membrane and allows water to leave the collecting duct and enter the
renal collecting duct cell where it eventually enters the blood (8) (Figure 1.3).

9

Figure 1.3 (left) Diagram of intracellular mechanism for vasopressin (AVP)
binding V2R (V2 Receptor) on basolateral membrane of a kidney collecting duct
cell increasing water reabsorption from the collecting duct which eventually
enters the bloodstream increasing arterial blood pressure. (Right) Diagram of
intracellular mechanism for AVP binding V1aR (V1a receptor) on vascular
smooth muscle cell increasing intracellular calcium and contraction leading to
increased vascular resistance and arterial blood pressure. Abbreviations:
(GDP) guanosine diphosphate, (GTP) guanosine triphosphate, (ATP)
adenosine triphosphate, (cAMP) cyclic adenosine monophosphate, (AC)
adenylyl cyclase, (PKA) protein kinase A, (AQP-2) aquaporin, (PLCβ)
phospholipase Cβ, (PIP2) phosphatidylinositol (4,5)-bisphosphate, (DAG)
diacylglycerol, (IP3) inositol (1,4,5)-triphosphate, (IP3R) inositol (1,4,5)triphosphate receptor, (ER) endoplasmic reticulum, (MAP) mean arterial
pressure, (TPR) total peripheral resistance, (CO) cardiac output. Adapted from
Birnbaumer et al. (8).

1.4 Salt Sensitive Hypertension
The blood pressure values that define hypertension are a systolic blood
pressure >140 mmHg or a diastolic blood pressure > 90 mmHg (14).
Hypertension can be classified based on etiology. If the cause is not known it is
termed essential or primary hypertension which accounts for most cases of
10

hypertension (10). Essential hypertension has the potential to be caused by a
wide range of factors because blood pressure is influenced by genetics,
behavior, and the environment (10). However, salt plays a central role in
essential hypertension since it has been shown the majority of individuals with
essential hypertension are salt sensitive (148) which suggests hypertension in
these individuals is largely dependent on salt intake.
Arguably one of the most prominent figures in the discovery of the
relationship between salt and hypertension is Dr. Lewis Dahl. Dahl was the first
to compare salt intake and the prevalence of hypertension between several
populations in the world. Using data from radiation research conducted by the
United States Atomic Energy Commission after WWII, Dahl found that
populations with higher salt consumption had a higher prevalence of
hypertension (32). Along with Dr. Dole and Cotzias, Dahl was also the first to
confirm in the 1950’s through human metabolic studies that the reduction in
blood pressure from Kempner’s rice-fruit diet, that had been previously found to
be useful for treatment of hypertension (70, 71), was due to its low sodium
content (40-42). Dahl later hypothesized that since a low salt diet lowered blood
pressure a high salt (HS) diet may cause an increase in blood pressure (33).
Dahl tested this hypothesis through a series of studies using an experimental
form of hypertension were Sprague-Dawley rats were fed a chronic HS diet
while their blood pressure was monitored. He found that some rats had no
blood pressure response and the rest of the rats developed varying degrees of
elevations in blood pressure (30, 31, 34). From these experiments it was
apparent to Dahl that genetic factors that determined susceptibility to salt were
responsible for the variations in blood pressure responses (37). This led to
development of the Dahl rat model of SSHTN.
1.4.1 Dahl Salt Sensitive Hypertension Model
In the 1960’s Dr. Lewis Dahl developed his animal model of SSHTN that
is still one of the most widely studied models today. Dahl fed Sprague-Dawley
(SD) rats a L-triiodothyronine-sea salt diet then selected and bred the rats that
developed the greatest elevations in blood pressure. He also selected and bred
11

rats that had no blood pressure response to the HS diet. Through repeated diet
treatment, selection, and inbreeding of both groups Dahl obtained entire
statistically different populations of rats that were very sensitive (Dahl saltsensitive rats (DS) and the other that was very resistant called (Dahl salt
resistant rats) to the development of HS induced hypertension (35-37). This
ability to isolate separate populations confirmed that the variability in blood
pressure in response to a high salt diet in the original unselected population of
SD rats was due to genetic factors that controlled sensitivity to salt rather than
due to statistical extremes of a homogenous population (37).
1.4.2 Vasopressin in Hypertension and Contribution to Dahl Salt Sensitive
Hypertension Model
Increased osmolality naturally results from hypernatremia and activates
osmoreceptors resulting in AVP release. Given AVP plays a role in blood
pressure regulation, It is logical that alterations in this essential physiological
response may therefore be a mechanism by which a HS diet can lead to the
development or maintenance of hypertension. However, In normal rats and
dogs long term administration of AVP to increase levels observed in
hypertension does not produced sustained hypertension (111, 134). This has
been demonstrated in dogs were AVP was infused for 3-4 weeks to increase
plasma levels to those observed in hypertension where water intake was
regulated to remain constant (134). MAP increased around 40 mmHg along
with an increase in body weight followed by a return of MAP and body weight
towards normal at the end of the two weeks. However, in dogs where total body
fluid volume was servo controlled MAP or body weight did not change over a
two-week period were the same amount of AVP was infused (21). This finding
supports the notion that the antidiuretic actions of AVP may be more important
than the vasoconstrictive actions of AVP in hypertension although additionally
AVP may not sustain hypertension in normal animals because it cannot sustain
blood volume expansion (25).
This phenomenon where the antidiuretic actions of AVP do not last is
called AVP escape. One mechanism of AVP escape is simply the kidneys
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intrinsic ability of pressure diuresis in response to elevated circulating AVP
causing blood volume expansion and elevated renal perfusion pressure since
long term administration of a subpressor dose of AVP in dogs with only 30% of
normal renal mass to reduce natriuresis and diuresis ability induced sustained
hypertension for 14 days (88). Blood pressure significantly increased within
three days of AVP administration and decreased back to normal within three
days when administration of AVP was stopped. Other mechanisms of AVP
escape include down regulation of V2 receptors in the inner medulla of the
kidneys (141), decreased expression of aquaporin-2 water channel in the renal
collecting duct (44), and Increased renal prostaglandin E2 (51). Also AVP may
not sustain hypertension due to its opposing actions on controlling blood flow to
the renal medulla resulting in its inability to chronically reduce renal medullary
blood flow. V1 receptor activation presumably on the medullary vasa recta
decreases renal medulla blood flow while V2 receptor activation increases renal
medulla blood flow (104). In conscious rats, chronic renal interstitial infusion of
an V1 receptor agonist significantly decreased inner medullary blood flow,
produced no change in cortical blood flow, and significantly increased MAP.
However chronic renal interstitial infusion of AVP which would activate V1 and
V2 receptors did not significantly decrease inner medulla blood flow or
significantly increase MAP (23). Evidence suggests V2 receptor activation in
the inner medulla collecting duct cells stimulates nitric oxide production which
may oppose V1 receptor action and increase medullary blood flow by
vasodilation of the medullary vasa recta (107).
Nevertheless enhanced AVP levels have been found in human
hypertension subjects (24, 109) and several animal models of experimental
hypertension such as spontaneously hypertensive rats (28, 99), partial
nephrectomy-salt

hypertension

(77),

deoxycorticosterone-salt

(DOC-salt)

hypertension (29), and renovascular hypertension (100). DS rats fed a HS diet
have greater plasma AVP levels compared to Dahl salt resistant rats fed a HS
diet (7, 90, 124, 146). However, the contribution of AVP to the Dahl model of
SSHTN is still controversial, as studies involving the administration of AVP
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antagonists to DS rats with salt induced hypertension have produced varying
results. Acute intravenous administration of the V1a receptor antagonist (CH2)5
VDAVP had no effect on the MAP of hypertensive DS rats fed a HS diet (90).
Oral administration of the V1a receptor antagonist OPC-21,268 prevented any
further increase in systolic blood pressure for the first 6 days of treatment in
male DS rats that were placed on an 8% NaCl HS diet 10 days prior (27).
However, this effect was transient and systolic blood pressure increased to
levels below control rats but not significantly different at the end of 12 days with
treatment of OPC-21,268. A More recent study showed that administration of a
dual AVP receptor antagonist RWJ-676070 produced a transient decrease in
MAP in hypertensive DS rats on a HS diet (53). These studies suggest AVP
contributes to HS induced hypertension in DS rats however hypertension in this
model is not completely dependent on AVP and other mechanisms contribute
as well. Interestingly chronic intravenous infusion of a subpressor dose of AVP
in DS rats significantly increased MAP after 1 day and after 14 days increased
MAP around 18 mmHg. Brown Norway rats that received the same treatment
did not show any change in MAP throughout the 14 days (150). This data
demonstrates DS rats are very sensitive to AVP. It has been hypothesized by
Gunnet et al. (53) that this enhanced sensitivity to AVP may also explain the
transient blood pressure reduction effects by AVP receptor antagonists in HS
fed DS rats.
In addition to the consequences elevated AVP levels may have on V1a
activation leading to increased vascular resistance, elevated AVP levels could
possibly contribute to Dahl SSHTN hypertension due to volume expansion. It
has been demonstrated that the development of hypertension in DS rats in
response to HS diet is volume dependent. Servo controlled prevention of blood
volume expansion prevented the rise of MAP in DS rats in response to HS
intake (20 mEq/ day sodium) suggesting blood volume expansion may be an
important factor in the BP development in the Dahl model (50). This is
consistent with the hemodynamics of DS rats on a 8% NaCl HS diet. After 4
weeks on a 8% NaCl HS diet it has been shown hypertension is mainly
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developed and maintained due to blood volume expansion causing increased
CO. At 8 weeks on an 8% NaCl HS diet CO is reduced (most likely due to
autoregulation to maintain consistent tissue flow) and hypertension is
maintained due to increased TPR (133). However, vasopressin has not been
directly linked to this blood volume expansion stage of hypertension in DS rats.
Despite the lack of evidence thus far that convincingly shows AVP contributes
the Dahl model of SSHTN, the central mechanisms that mediate enhanced
AVP levels found in this model are not well known.

1.5 Orexin
The neuropeptides orexin A and orexin B (also known as hypocretin 1
and hypocretin 2) were first discovered independently in 1998 by two different
groups. Sakurai et al. identified two neuropeptides isolated from rat brain tissue
that were produced from the same precursor polypeptide by proteolytic
processing (120). They found that both peptides were ligands of two closely
related G protein-coupled receptors that had no previously known ligands.
When centrally administered in rats, both peptides stimulated increased food
consumption and the precursor polypetide mRNA was upregulated in 48 hour
fasted rats. Therefore, they called these peptide ligands orexins (orexin A and
orexin B) similar to the greek word orexis meaning appetite, and the G proteincoupled receptors they activated orexin receptor 1 (OX1R) and orexin receptor
2 (OX2R). They termed the precursor polypeptide prepro-orexin and the
messenger mRNA that encoded it prepro-orexin mRNA (120). Sakurai et al.
was the first to describe in detail the structure of the orexins produced from
prepro-orexin polypeptide. Orexin A is a 33 amino acid peptide with two
intrachain disulfide bonds while orexin B is a linear 28 amino acid peptide (120).
They also found that orexin A and orexin B bind OX2R with equal affinity while
orexin A binds to the OX1R with a higher affinity than orexin B (120).
Independently de Lecea et al. identified the mRNA for the same
precursor peptide and predicted this peptide was cleaved to form a pair of
peptides (39). They called these peptides hypocretin 1 and hypocretin 2
because their amino acid sequence was similar to members of the hormone
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family the incretins and because they found the messenger mRNA and
precursor polypeptide to be located in cell bodies of neurons in the
hypothalamus (39).
Soon

after

the

discovery

of

orexin

subsequent

major

immunohistochemistry studies examined where orexin producing neurons were
localized in the brain and the regions of the brain that these neurons projected
to. The cell bodies of neurons containing orexins were found to be exclusively
localized only in the hypothalamus particularly in the lateral hypothalamic area,
perifornical nucleus, dorsomedial hypothalamic nucleus, dorsal hypothalamic
area, and posterior hypothalamic area (38, 105, 113) in the rat brain. However,
these orexin containing neurons have widespread projections throughout the
entire brain including the cerebral cortex, thalamus, circumventricular organs,
limbic system, and brainstem as well as throughout the hypothalamus (38, 105,
113). Consistent with this extensive projection throughout the brain orexin A
and orexin B are reported to function as excitatory neurotransmitters (39, 72,
138) and regulate numerous physiological processes including sleep and
arousal (11, 138), feeding behavior (45, 61, 66, 120), emotion (68, 76), reward
(59), and energy homeostasis (101) processes. Accumulation of studies now
suggest the orexin system serves an overall function of receiving internal and
external environment information and serves to regulate arousal and autonomic
function to support motivated behaviors (119).

1.5.1 Orexin Control of Cardiovascular Function
Studies suggest one of the autonomic functions the orexin system
regulates is the central nervous system control of cardiovascular function.
Prepro-orexin knockout mice exhibit a lower basal arterial pressure in both
anesthetized and conscious conditions (69). Also rats with genetic ablation of
orexin neurons have lower systolic and diastolic pressure in both sleep and
wake states (123). Central administration of orexin A and orexin B increases
HR, MAP, and SNA in conscious (84, 91, 121, 129, 131) and anesthetized
animals (4, 12, 125, 126) indicating one mechanism orexin A regulates
circulation and blood pressure is through regulating SNA. The orexin system
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has also been implicated in AVP regulation. ICV administration of orexin A
increases AVP mRNA in parvocellular neurons of the PVN in conscious rats (1)
and also plasma AVP levels in conscious rabbits (91). These findings are
consistent with orexin containing nerve terminals (6, 15, 16, 105, 113, 126, 151)
and

receptors

from

in-situ

hybridization

studies

(83,

89,

144)

and

immunohistochemistry studies (5, 18, 62) residing in many cardiovascular
control regions of the brain including both magnocellular and parvocellular
neurons of the PVN. Studies focusing on the action of orexin in the PVN have
shown that orexin-A has excitatory actions by depolarizing both magnocellular
and parvocellular neurons (47, 122, 130). The actions of orexin-A on
magnocellular and parvocellular PVN neurons based on current evidence are
shown in figure 1.4.

Figure 1.4 Orexin-A depolarizes magnocellular and parvocellular
paraventricular nucleus (PVN) neurons. Orexin-A may activate either glutamate
containing presynaptic or interneurons increasing glutamate release to
magnocellular PVN neurons activating postsynaptic glutamate receptors
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(GlutR). Orexin-A may also enhance postsynaptic glutamate receptor function
in magnocellular PVN neurons. Orexin-A depolarizes parvocellular PVN
neurons through activation of non-selective cation channels (NSCC).
Abbreviations: orexin receptor 1 (OX1R), orexin receptor 2 (OX2R). Figure
based on data from Follwell and Ferguson (47).
1.5.2 Orexin System Contributes to Hypertension
Accumulating evidence indicates that hyperactivity of the orexin system
contributes to several animal models of hypertension. Oral administration of the
dual orexin receptor antagonist almorexant significantly decreased systolic
blood pressure, diastolic blood pressure, MAP, and HR compared to pre
treatment in conscious spontaneously hypertensive rats in both wakefulness
and sleep during dark and light periods of the diurnal cycle (81). However, the
same dose of the dual orexin receptor antagonist did not affect blood pressure
or HR in Wistar Kyoto rats (81). This study suggests that over activation of the
orexin system contributes to the maintenance of hypertension in the SHR
hypertension model. Furthermore, ICV administration of an OX2R antibody or
antagonist and RVLM injection of an OX2R antagonist results in a significant
reduction in MAP and HR in spontaneously hypertensive rats but not in Wistar
Kyoto rats (78). This study suggests that elevated OX2R activity in the RVLM
contributes to hypertension in the spontaneously hypertensive rat model.
The orexin system has also recently been implicated in the obese
Zucker rat model of obesity-related hypertension. Microinjection of the OX1R
antagonist SB334867 into the PVN significantly decreased MAP and renal
sympathetic nerve activity (RSNA) in obese Zucker rats but not in lean Zucker
rats (152). PVN OX2R blockade did not affect MAP or RSNA in obese Zucker
rats or lean Zucker rats. PVN OX1R protein levels were significantly greater in
15 week old obese Zucker rats compared to lean Zucker rats (152). Additionally
orexin A induced a greater increase in firing rate of spinally projecting PVN
neurons in obese Zucker rats compared to lean Zucker rats which was
attenuated by OX1R antagonist SB334867 but not OX2R antagonist TCS OX2
29 (152). This study suggests that upregulation of the OX1R contributes to
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enhanced neuronal activity of PVN neurons and contributes to augmented SNA
and hypertension in the obese Zucker rat model of obesity related hypertension.
However, the role orexin plays in SSHTN is unknown.

1.6 Summary and Hypothesis
AVP

production

and

release

is

a

homeostatic

response

to

hyperosmolality following salt ingestion and is involved in blood pressure
control. It has been demonstrated that enhanced AVP levels associated with
DS rats on a HS diet may contribute to Dahl SSHTN. However, the central
mechanisms were HS stimulation may increase AVP levels and contribute to
SSHTN are not well known. Based on recent evidence that increased activity of
the brain orexin system is involved in hypertension we sought to investigate its
involvement in SSHTN. Previous studies on the orexin systems role in
hypertension have focused on orexin mediated changes in SNA therefore, we
intended to focus on orexin mediated changes in AVP signaling. Taking into
account the importance of the PVN in AVP and blood pressure control, and that
orexin is involved in the regulation of PVN neuronal activity and AVP regulation
we hypothesized that increased activity of the orexin system in the PVN may be
responsible for enhanced AVP levels in HS fed DS rats.
The link between how increased salt intake could activate the orexin
system is unclear at the present time. There is no direct evidence that
orexinergic neurons are osmosensitive or receive input from osmoreceptors in
the lamina terminalis. However, it has previously been shown that prepro-orexin
mRNA is upregulated In the hypothalamus of 48 hour water deprived rats (75)
indicating orexin producing neurons may be sensitive to changes in osmolality.
Additionally, the lamina terminalis has been shown to have projections to the
lateral hypothalamus (58, 65), a region where the cell bodies of orexin
producing neurons are found.
In DS rats a combination of genetic abnormalities may lead to chronic
activation of the orexin system in the PVN in response to elevated salt intake. It
has been demonstrated that DS rats have genetic functional abnormalities of
the kidneys that reduced natriuresis or the ability to excrete salt (85). It has
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been shown that in response sodium is abnormally sequestered in the CSF
(132). Specifically, it has been shown that the CSF sodium concentration of DS
rats increased to 6mM after 6 days on an 8% HS diet before development of
hypertension hypertension (64). It has been previously hypothesized that CSF
sodium concentration is increased in response to sodium retention in DS rats
(132). Abnormal transport across the choroid plexus (2) may be responsible for
increased CSF sodium concentration in DS rats.
Given this evidence in DS rats, it is plausible that in response to a HS
diet reduced ability of the kidneys to excrete salt may cause cerebrospinal fluid
(CSF) sodium concentration to increase as hypothesized by Simchon et al.
(132). The circumventricular organs in the lamina terminalis may sense
increased osmolality due to elevated CSF sodium concentration which may
subsequently activate orexin producing neurons located in the hypothalamus.
Alternatively increased CSF sodium concentration may directly activate orexin
producing neurons. This may result in increased orexin release to the PVN
which could potentially increase PVN neuronal activity resulting in enhanced
AVP secretion. Elevated plasma AVP levels may then play a role in the Dahl
model of SSHTN through its vasoconstrictive or antidiuretic actions. In addition,
the reduced ability of natriuresis by the kidneys of DS rats may support chronic
activation of the orexin system and may explain why orexin producing neurons
would not be chronically activated in SD or Dahl salt resistance rats in response
to a high salt diet. This hypothesis is shown in figure 1.5.
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Figure 1.5 Hypothesis for high salt (HS) induced activation of the orexin system
in the paraventricular nucleus (PVN) leading to enhanced vasopressin (AVP)
levels in Dahl salt sensitive rats. A HS diet may increase cerebrospinal fluid
(CSF) fluid sodium concentration. Circumventricular organs (CVO) in the
lamina terminalis may sense increased osmolality and activate orexin
producing neurons. This may increase orexin release to the paraventricular
nucleus and activate magnocellular (Ma) neurons and increase release of
vasopressin (AVP) into the blood. Elevated blood AVP levels may contribute to
hypertension in this model through vasoconstriction or increased water
reabsorption. Reduced ability of natriuresis by the kidneys of Dahl salt sensitive
rats may support chronic activation of the orexin system and may explain why
orexin would not be chronically activated in Sprague Dawley or Dahl salt
resistance rats in response to a high salt diet. Whether parvocellular (Pa) pre
sympathetic neurons are activated by orexin and result in increased
sympathetic nerve activity (SNA) contributing to hypertension in this model
remains to be determined. (MAP) mean arterial pressure, (TPR) total peripheral
resistance, (CO) cardiac output.
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Chapter 2. Methods
2.1 Animals
All rats used in this study were purchased from Charles River
Laboratories (Wilmington, MA). Eight-week-old male adult DS and age and sex
matched SD rats were placed on either a normal salt (NS), 0.4% NaCl diet or
HS 8% NaCl diet (Envigo RMS, IN, USA) for 5 weeks, and used for blood
pressure measurement, brain mRNA measurement, and sympathetic nerve
activity recording. Adult male SD rats (350-500 g) were used for brain
intracerebroventricular (ICV) infusion. Cultured hypothalamic neurons were
obtained from newborn SD rats. All animals were housed in two rats per cage
and kept on a 12:12-h light-dark cycle in a climate-controlled room. Rat chow
and water were provided ad libitum. All of the animal experiments followed
protocols that were approved by the Michigan Technological University
Institutional Animal Care and Use Committee.

2.2 Blood Pressure Measurement
Prior to diet treatment eight week old male adult DS rats were
anesthetized with isoflurane (3%) and telemetry transmitters were implanted
into the abdominal aorta, and arterial pressure was monitored as described
previously (128). Blood pressure in age and sex matched SD rats was
monitored during diet treatment via volume pressure tail cuff method.

2.3 Real-time PCR Analysis of PVN Fra1, AVP, Prepro Orexin, OX1R,
and OX2R mRNA Expression
Eight-week-old male adult DS rats and age and sex matched SD rats
were placed on an either a normal salt (NS), 0.4% NaCI diet or HS 8% NaCI
diet for 5 weeks. After diet treatment animals were euthanized, brains were
removed and PVN tissue was punched. Punched PVN tissues were subjected
to RNA isolation, using RNeasy plus Mini kit (Qiagen, CA, USA) following the
manufacturer’s instructions.

The material contained in this chapter is in preparation for submission to a journal.
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Real-time PCR was performed to measure mRNA levels of Fra1, AVP, prepro
orexin, OX1R, and OX2R using the specific primer and probe (Applied
Biosystems, Foster City, CA) in the Step One Plus Real Time PCR System
(Applied Biosystems). Data were normalized to GAPDH mRNA.

2.4 Preparation of Neuronal Cultures
Primary neuronal cultures were made from the hypothalamus
containing the PVN of 1-day-old SD rats as described previously (127). Briefly,
rats were euthanized and the hypothalamus was immediately dissected and
tissues were combined. Neurons were dissociated from each other and plated
in poly-L-lysine culture dishes.

Neuronal cultures contained >95% neurons

(remaining cells were primarily astroglia). The cultures were maintained for 10–
14 days before their use in experiments.

2.5 Measurement of Orexin A Effect on AVP Expression in Cultured
Brain Neurons
Primary neuronal cultures from the hypothalamus of 1-day old SD rats
were incubated with vehicle control or differing concentrations of orexin (10nM,
100nM, 1μM, 10μM) for 6 hours. The cells were collected, RNA was isolated,
and real-time PCR was performed to measure mRNA levels of AVP. We then
coincubated neuronal cultures with 1μM orexin with or without the orexin
receptor 1 antagonist (OX1Ra) SB-408124 (100 µM) or orexin receptor 2
antagonist (OX2Ra) TCS OX2 29 (100 µM) (Tocris Bioscience, united,
Kingdom) for 6 hours. The mRNA level of AVP was determined by quantitative
real-time PCR as described in the methods. Each set of experiments was
performed using three separate culture dishes, and all cDNA samples were
assayed in duplicate. The whole experiment was repeated three times. Data
were normalized to GAPDH mRNA.

2.6 Intracerebroventricular (ICV) Injections
Adult male SD rats (350-500 g) were anesthetized with isoflurane (3% in
O2). Body temperature was held at 37°C with a water-circulating pad. Animals
were placed in a stereotaxic head frame, and the skull was leveled between
bregma and lambda. A small piece of skull was removed so that a Hamilton
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syringe could be lowered vertically into the left lateral ventricle. The stereotaxic
coordinates for I.C.V injection into the left lateral ventricle were: 0.8–0.9 mm
caudal to bregma; 1.4–1.8 mm lateral to midline; and 3.2–3.8 mm ventral to
dura. Each rat received only one injection. For I.C.V injection, vehicle control
(0.9% saline) was injected at a fixed volume of 2 μl over 2 min., orexin A
(.2nmol) was injected at a fixed volume of 4 μl over 5 min., and hypertonic
saline (4 µmol) was injected at a fixed volume of 2 μl over 2 min. Orexin A
(Sigma-Aldrich, St. MO, USA) was dissolved in 0.9% saline. Drugs were
injected into the left lateral ventricle using a UltraMicroPump3 (WPI). Three
hours following ICV injection, rats were euthanized and brain PVN tissues were
punched out and received real time PCR analysis for AVP mRNA expression
as described in this section.

2.7 Experimental Preparation for Sympathetic Nerve Activity
Recordings
Animal surgery was performed following the previously described
protocol (52). Briefly, rats were anesthetized with an intraperitoneal injection
containing a mixture of α-chloralose (80 mg/kg) and urethane (800 mg/kg).
Adequate depth of anesthesia was assessed before surgery by the absence of
pedal and corneal reflexes and by failure to withdraw the hindlimb in response
to pinching the paw. Animals were instrumented with an arterial catheter
inserted into the aorta through a femoral artery. The catheter was connected to
a pressure transducer to measure arterial blood pressure (ABP). Heart rate
(HR) was obtained from the R-wave of the electrocardiogram (ECG) (lead I). A
catheter was also placed in the left femoral vein to administer drugs. After
tracheal cannulation, rats were paralyzed with gallamine triethiodide (25
mg·kg−1·h−1 iv) and artificially ventilated with oxygen-enriched room air. After
paralysis, adequate depth of anesthesia was determined by lack of pressor
responses to noxious foot pinch. Supplemental doses of anesthesia equal to
10% of the initial dose were given when needed. End-tidal PCO2 was
continuously monitored and maintained within normal limits (35–40 mmHg) by
adjusting ventilation rate (80–100 breaths/min) and/or tidal volume (2.0–3.0 ml).
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Body temperature was held at 37°C with a water-circulating pad.

2.8 Sympathetic Nerve Activity (SNA) Recording
SNA recording was performed as previously described (52, 137). With
the use of a left flank incision, a left renal and splanchnic sympathetic nerve
bundle was isolated from surrounding tissue and mounted on a stainless steel
wire electrode (0.127-mm OD; A-M Systems), and covered with a silicon-based
impression material (Coltene, Light Body) to insulate the recording from body
fluids. The recorded signal was directed to an AC amplifier (P511; Grass
Technologies) equipped with half-amplitude filters (band pass: 100-1,000 Hz)
and a 60-Hz notch filter. The processed signal was rectified, integrated (10-ms
time constant), and digitized at a frequency of 5,000 Hz using a 1401 Micro3
analog-to-digital converter and Spike 2 software (7.04 version; Cambridge
Electronic Design, Cambridge, UK). The background noise was determined by
a bolus injection of hexamethonium (30 mg/kg iv), a ganglionic blocker, at the
end of the experiment and was subtracted from all the integrated values of
SNA.

2.9 Paraventricular Nucleus (PVN) Injections
PVN injections were performed as previously described (52). Animals
were placed in a stereotaxic head frame, and the skull was leveled between
bregma and lambda for PVN injections. A small piece of skull was removed so
that a single-barreled glass microinjector pipette could be lowered vertically into
the PVN. The stereotaxic coordinates for PVN injections were the following:
1.2–1.6 mm caudal to bregma; 0.5–0.7 mm lateral to midline; and 7.0–7.4 mm
ventral to dura. The OX1R antagonist SB408124 (Santa Cruz Biotechnology,
Texas, USA) was dissolved in DMSO. SB408124 (30pmol) was microinjected
into the PVN bilaterally in a volume of 50 nl per side with a pneumatic pump
(WPI). The approximate interval between two bilateral injections was ∼5 min.
The volume of each injection was determined by measuring the movement of

the fluid meniscus within the microinjector pipette using a dissecting
microscope equipped with an eyepiece reticule. At the end of each experiment,
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Chicago blue dye solution (2% in saline, 50 nl) was injected into the PVN to
mark the site of each injection. Brains were removed and post fixed for 5 days
at room temperature in 4% paraformaldehyde. Brain coronal sections
containing the PVN were cut, and microinjection sites were identified under light
microscopy. Rats with injection site(s) not inside the PVN were excluded from
data analysis.

2.10

Data analysis
Summary data are expressed as means ± SEM. For SNA recording

splanchnic sympathetic nerve activity (SSNA) and RSNA were determined as
an average of the rectified, integrated signal. Baseline values of all recorded
variables were obtained by averaging a 10-min segment of data recorded
immediately before PVN microinjection in anesthetized rats. SSNA, RSNA, and
MAP responses to OX1Ra SB408124 were obtained by averaging a 2-min
period centered on the maximal response. Data are presented as percent (%)
change from baseline after subtracting background noise determined with bolus
injection of the ganglionic blocker hexamethonium (30 mg/kg). Both in vivo and
in vitro data were analyzed using either a one-way anova or unpaired student ttest. Post hoc analysis was performed with Newman-Keuls multiple comparison
test. Differences were considered statistically significant at a critical value of P
< 0.05.
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Chapter 3. Results
3.1 High Salt Diet Increases Blood Pressure in DS Rats
In order to confirm a HS diet induces hypertension in DS but not SD rats,
eight-week-old male adult DS rats and age and sex matched SD rats were
placed on either a NS, 0.4% NaCl diet or HS 8% NaCl diet for 5 weeks. Blood
pressure was monitored via telemetry transducer. SD rats on a HS diet showed
no change in MAP compared to NS diet SD rats (HS: 108±2 vs NS: 105 ± 1
mmHg). DS rats on a HS diet had significantly (P<0.05) increased MAP (HS:
159 ± 6 vs. NS: 111 ± 1 mmHg) compared to NS diet DS rats (Figure 3.1).

Figure 3.1 Conscious mean arterial pressure (MAP) for Sprague Dawley (SD)
rats and Dahl salt sensitive rats (DS) after 5 weeks on a normal salt (NS; 0.4%
NaCl) and high salt (HS; 8% NaCl) diet.

3.2 High Salt Diet Increases PVN mRNA levels of Fra1, AVP, OX1R,
and Prepro Orexin in DS Rats
Next, we sought to determine if a HS diet alters PVN AVP and orexin
system component expression in SD and DS rats. Eight-week-old male DS rats

The material contained in this chapter is in preparation for submission to a journal.
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and age and sex matched SD rats were divided into two groups and were fed
either a NS (0.4%) or HS (8% NaCI) diet for 4-6 weeks.The rats were then
euthanized, PVN tissue was punched out and real time PCR was performed to
assay the chronic neuronal activation marker Fra1, AVP, prepro orexin, OX1R,
and OX2R mRNA levels. SD rats on a HS diet showed no significant change in
PVN mRNA levels of Fra1 (HS: 1.46±0.37 vs. NS:1.0±0.18 fold; n=4-6; P>0.05),
OX1R (HS: 1.21±0.06 vs. NS:1.0±0.13 fold; n=4-6; P>0.05), or OX2R (HS:
0.82±0.05 vs. NS:1.0±0.17 fold; n=4-6; P>0.05), compared to NS diet SD rats.
SD rats on HS intake showed significantly increased PVN mRNA levels of AVP
(HS: 1.52±0.09 vs. NS:1.0±0.09 fold; n=3-6; P<0.05), compared to NS intake
SD rats (Figure 3.2). HS intake induced significant increases in PVN mRNA
levels of Fra1(HS: 2.4±0.48 vs. NS:0.93±0.13; n=6; P<0.05), AVP (HS:
2.4±0.46 vs. NS: 1.0±0.09; n=5-6; P<0.05), prepro orexin (HS: 2.5±0.46 vs. NS:
1.0±0.28; n=7; P<0.05), and OX1R (HS: 1.5±0.09 vs. NS: 1.0±0.09; n=7;
P<0.05) in DS rats (Figure 3.3).

Figure 3.2 Real time PCR analysis of chronic neuronal activation marker Fra1,
vasopressin (AVP), orexin receptor 1 (OX1R), and orexin receptor 2 (OX2R)
mRNA expression levels in the paraventricular nucleus (PVN) between normal
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salt (NS; 0.4% NaCl) and high salt (HS; 8% NaCl) Sprague Dawley (SD) rats.
HS diet did not change Fra1, OX1R, or OX2R but significantly increased AVP
PVN mRNA expression. The mRNA level in the control sample was assigned to
be arbitrary unit (a.u) 1. *p≤0.05 vs. NS diet; n=3-6 each group.

Figure 3.3 Real time PCR analysis of chronic neuronal activation marker Fra1,
vasopressin (AVP), orexin receptor 1 (OX1R), and prepro orexin mRNA
expression levels in the paraventricular nucleus (PVN) between normal salt
(NS; 0.4% NaCl) and high salt (HS; 8% NaCl) Dahl salt sensitive (DS) rats. HS
diet results in increases in mRNA levels of Fra1, AVP, OX1R, and prepro
orexin in the PVN. The mRNA level in the control sample was assigned to be
arbitrary unit (a.u) 1. *p≤0.05 vs. NS diet; n=5-7 each group.

3.3 ICV Orexin A induces increases in PVN AVP mRNA expression
and Orexin A Induced Increases in AVP mRNA levels are
Attenuated by OX1R Blockade in cultured Hypothalamic
Neurons.
We hypothesized from the results from the above study that increased
orexin receptor activation (OX1R or OX2R) in the PVN may be responsible for
the enhanced PVN AVP levels in the HS intake DS rats. First In order to
confirm orexin-A controls PVN AVP expression in vivo, male adult SD rats
29

received ICV injection of orexin-A (0.2 nmol). Three hours following injection,
rats were euthanized and brain PVN tissues were punched out and received
real time PCR analysis to determine AVP mRNA expression. The results
showed that AVP mRNA levels were significantly increased 4.9-fold in orexin A
injection rats (n=7) compared to vehicle control injected rats (P<0.05) (Figure
3.4).

Figure 3.4: Real time PCR analysis of paraventricular nucleus (PVN)
vasopressin (AVP) mRNA expression levels at three hours following acute
intracerebroventricular (ICV) infusion of vehicle control (0.9% saline) and orexin
A (0.2 nmol) using male adult Sprague Dawley (SD) rats. The mRNA level in
the control sample was assigned to be arbitrary unit (a.u) 1. *p≤0.05 vs. vehicle
control; n=7.
Next we determined which orexin receptor is responsible for the regulation of
vasopressin (AVP) signaling. Primary neuronal cultures from the hypothalamus
of new born SD rats containing the PVN were incubated with differing
concentrations of orexin for six hours. Real time PCR was performed to assay
mRNA levels of AVP. The results indicate that orexin treatment resulted in a
dose dependent increase in AVP mRNA levels (100nM: 2.5-fold; 1μM; 4.8 fold;
10μM: 15.7-fold) (n=4) (Figure 3.5 left). Next to determine the orexin receptor
type responsible for inducing increased AVP expression, primary neuronal
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cultures from the hypothalamus of new born SD rats were incubated with orexin
alone or co-incubated with orexin A and the orexin receptor 1 antagonist
(OX1Ra SB408124) or the orexin receptor 2 antagonist (OX2Ra TCS OX2 29)
for 6 hours. Real time PCR was performed to measure AVP mRNA levels. The
results showed that orexin (1μM) induced increases in AVP (2.7 fold) mRNA
were attenuated by OX1Ra (1.2 fold) (P<0.05) but not OX2Ra (2.1 fold) (n=4)
(Figure 3.5 right).

Figure 3.5 Left: Incubation of primary neuronal cultures from the hypothalamus
of new born Sprague Dawley (SD) rats containing the paraventricular nucleus
(PVN) with increasing concentrations of orexin for six hours, the neurons were
then collected, RNA was purified, and real time PCR was performed to assay
mRNA levels of AVP. *p ≤0.05 vs.control; n=4 each group. Right: Incubation of
primary neuronal cultures from the hypothalamus of new born SD rats
containing the PVN with orexin alone or co-incubated with an orexin receptor 1
antagonist (OX1Ra) SB408124 or orexin receptor 2 antagonist (OX2Ra) TCS
OX2 29 for 6 hours. Real time PCR was performed to measure AVP mRNA
levels. Orexin A induced increase in mRNA levels of vasopressin (AVP) are
attenuated by OX1R but not OX2R blockade in hypothalamic neurons. The
mRNA level in the control sample was assigned to be arbitrary unit (a.u) 1. *p
≤0.05 vs.control. #p≤0.05 vs. orexin/OX1Ra. Ŧ P≤0.05 vs. orexin/OX1Ra
treatment; n=4 each group.

3.4 Acute ICV Injection of Hypertonic Saline Increases PVN OX1R
and AVP mRNA Levels in SD rats
The results from the above study suggest that orexin controls PVN AVP
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expression through OX1R activation. This suggests that increased PVN OX1R
activation, potentially via upregulation, may cause enhanced PVN AVP
signaling in HS intake DS rats. It has been previously shown that CSF sodium
concentration increases in DS rats on a HS diet t (64, 103). Therefore, we
hypothesized that increased CSF sodium concentration in HS intake DS rats
may cause PVN OX1R upregulation leading to enhanced PVN AVP signaling. It
has previously been demonstrated that CSF sodium concentration of DS rats
increased by 6mM after 6 days on an 8% HS diet (64). Therefore, we expect
that after 4-6 weeks of 8% HS diet, CSF sodium concentration should increase
by no less than 10mM. Assuming the entire CSF volume is 400 μl (142), ICV
injection of 4 μmol NaCl should increase the CSF sodium concentration by
10mM. Male adult SD rats received ICV injection of hypertonic saline (4 μmol)
in order to mimic increased CSF sodium concentration of DS rats on a HS diet
for 5 weeks as used in our study. Three hours following injection PVN tissue
was punched, RNA was extracted and reverse transcribed to cDNA and real
time PCR was performed to determine PVN mRNA levels of OX1R, OX2R, and
AVP. The results showed that OX1R (1.4 fold) but not OX2R (0.97 fold) PVN
mRNA levels were significantly increased (P<0.05) in hypertonic saline injection
rats compared to vehicle control injection rats. AVP mRNA levels were
significantly increased (4.8-fold) in hypertonic saline injection rats (n=5)
compared to vehicle control injected rats (P<0.05) (Figure 3.6).
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Figure 3.6 Real time PCR analysis of paraventricular nucleus (PVN) OX1R,
OX2R, and vasopressin (AVP) mRNA expression levels at three hours
following acute intracerebroventricular (ICV) infusion of vehicle control (0.9%
saline) and hypertonic saline (4 μmol) using male adult Sprague Dawley (SD)
rats. The mRNA level in the control sample was assigned to be arbitrary unit
(a.u) 1. *p≤0.05 vs. vehicle control; n=4-7 each group.

3.5 OX1R Blockade in PVN Reduces Blood Pressure in HS Diet DS
Rats
The results from the above studies indicate a HS diet increases PVN
OX1R expression in DS rats, the OX1R mediates AVP signaling in the PVN,
and increased CSF sodium concentration in HS intake DS rats may cause PVN
OX1R upregulation leading to enhanced AVP signaling. Therefore, we
hypothesized that increased OX1R activation in the PVN contributes to the
maintenance of hypertension in HS intake DS rats. To test this hypothesis we
recorded the MAP, SNA, and HR response to bilateral PVN microinjection of
the OX1R antagonist SB408124 in anaesthetized DS rats fed a NS and HS diet
for 5 weeks. OX1R antagonist SB408124 bilaterally injected into the PVN
significantly decreased MAP in DS rats fed a HS diet compared to DS rats with
NS intake. OX1R blockade increased SSNA and RSNA in NS and HS DS rats.
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Figure 3.7 A-B (left panels) Shows an example of the SSNA, RSNA, and MAP
responses

to

orexin

receptor

1

antagonist

(OX1Ra)

SB408124

(30

pmol/50nl/side) into DS rats fed a NS diet (.4%). Maximum increases in SSNA
and RSNA were (35.82±9%; n=5) and (17.4±10%; n=6) respectively. The
maximum decrease in MAP was (-4±4 mmHg; n=6). Figure 3.7 A-B (right
panels) Shows an example of the SSNA, RSNA, and MAP responses to
SB408124 (30 pmol/50nl/side) into DS rats fed a HS diet (8%). Maximum
increases in SSNA and RSNA were greater in HS rats compared to NS rats but
failed to reach statistical significance (HS: 48.2±12.6%; n=5 vs. NS: 35.82±9%;
n=5, P=0.2) and (HS: 26.7±7.5%; n=5 vs. NS: 17.4±10%; n=6, P=0.2)
respectively. The maximum decrease in MAP was greater in HS rats compared
to NS rats (HS: -16±5 mmHg; n=5 vs. NS: -4±4 mmHg; n=6, P<0.05). Figure
3.8 shows PVN microinjection summary data. Figure 3.9 shows a single
representative PVN injection. It was found in four rats that dye was injected into
the third ventricle therefore the results from these rats were not included for
data analysis.
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Figure 3.7 A: Representative traces showing splanchnic sympathetic nerve
activity (SSNA), renal sympathetic nerve activity (RSNA), and mean arterial
blood pressure (MAP) responses to bilateral PVN microinjections of Orexin
receptor 1 antagonist (OX1Ra) SB408124 (30 pmol/50nl/side) into DS rats fed
a normal salt diet (0.4%) left and DS rats fed a high salt diet (8%) right. B: Left
column, 2.5-s specimen traces of SSNA (top) and RSNA (bottom) before
injection of OX1Ra into the PVN and after microinjection of OX1Ra into the
PVN of a DS rat on NS diet. Right column, 2.5-s specimen traces of SSNA
(top) and RSNA (bottom) before injection of OX1Ra into the PVN and after
microinjection of OX1Ra into the PVN of a DS rat on HS diet. PVN orexin
receptor 1 blockade reduces blood pressure in DS rats with high salt intake.
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Figure 3.8 Summary data showing changes in splanchnic sympathetic nerve
activity (SSNA), renal sympathetic nerve activity (RSNA), mean arterial
pressure (MAP), and heart rate (HR) in response to paraventricular nucleus
(PVN) bilateral microinjections of orexin receptor 1 antagonist SB408124 (30
pmol/50nl/side) in NS DS rats (n=5-6) and HS DS rats (n=5). *P<0.05
compared to NS.

Figure 3.9 Representation of a single injection (50nl) within the PVN.
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Chapter 4. Discussion
Accumulating evidence suggests that the orexin system is involved in
the central control of cardiovascular function and its hyperactivity in the brain
contributes to hypertension (78, 79, 81, 152), however, the role of orexin in the
SSHTN is not known. This study is the first to investigate the contribution of the
orexin system to SSHTN. We report six findings. First MAP is increased in DS
rats with HS intake. Second, Fra1, AVP, OX1R, and prepro orexin mRNA
expression are upregulated in the PVN in DS rats with HS intake. Third, ICV
administration of orexin A increased PVN AVP mRNA expression in SD rats.
Fourth, Incubation of cultured hypothalamic neurons from SD rats containing
the PVN with orexin increases AVP mRNA expression which is blocked by coincubation with an OX1R antagonist. Fifth, ICV administration of hypertonic
saline increase PVN OX1R and AVP mRNA levels in SD rats. Finally, PVN
OX1R antagonist injection significantly reduces MAP in DS rats fed a HS diet
compared to NS fed DS rats. Taken together, these findings indicate that
increased OX1R activity in the PVN contributes to enhanced AVP signaling in
DS rats on a HS diet which may contribute to the maintenance of Dahl SSHTN.
The PVN is a key site for the integration of autonomic and
neuroendocrine function, and its function is essential to maintain elevated BP in
Dahl SSHTN (49). Expression of orexin (15, 16, 105, 113, 126, 151) and its
receptors (5, 18, 62, 83, 89, 144) are widespread in regions of the brain
involved in blood pressure regulation including the PVN. Our study is novel in
that it shows that mRNA expression levels of the orexin precursor prepro orexin
and OX1R are higher in the PVN of DS rats on a HS diet compared to DS rats
on a NS diet (Figure 3.3). Our results also showed that DS rats on a HS diet
had increased PVN AVP mRNA levels consistent with previous findings that
plasma AVP is elevated in DS rats on a HS diet (90, 124, 146). We did not
observe PVN mRNA expression of components of the orexin system in the

The material contained in this chapter is in preparation for submission to a journal.

37

PVN to be changed in HS fed SD rats (Figure 3.2). These results indicate that
a HS diet may be linked to increased PVN orexin system activity in DS rats.
Consistent with previous studies and as expected we found that 5 weeks HS
8% NaCl diet significantly increased MAP in DS rats but not SD rats (Figure
3.1).
Based on these results we hypothesized that increased PVN orexin
system activity may be responsible for increased AVP signaling in the PVN in
HS DS rats. First, we sought to confirm that orexin A controls PVN AVP
expression in vivo. ICV infusion of orexin A significantly augmented PVN AVP
mRNA expression compared to vehicle control (Figure 3.4). This is consistent
with a previous study showing ICV injection of orexin A increased PVN AVP
mRNA expression in conscious rats (1) and ICV administration of orexin A
significantly increased plasma AVP levels in conscious rabbits after 90 minutes
(91). Next, we sought to determine the receptor type orexin A may control AVP
signaling in the PVN. We performed this study in vitro using cultured neurons
from the hypothalamus containing the PVN from newborn SD rats. Incubation
of cultured brain neurons with orexin A resulted in a dose dependent increase
in AVP mRNA expression (Figure 3.5). Co-incubation with an OX1R but not
with an OX2R antagonist attenuated this orexin induced AVP mRNA
expression response (Figure 3.5). Taken together these results indicate that
activation of the OX1R expressed on PVN neurons is likely responsible for
orexin induced AVP mRNA expression. This suggest that increased PVN OX1R
activation potentially via upregulation contributes to enhanced PVN AVP
signaling of DS rats on a HS diet.
DS rats on a HS diet are associated with increased CSF sodium
concentration (64, 103) which precedes hypertension (64). It was found the
CSF sodium concentration of DS rats but not Dahl salt resistant rats increased
by 6mM after 6 days on an 8% HS diet preceding hypertension (64). Therefore,
we hypothesized that increased CSF sodium concentration in HS intake DS
rats may cause PVN OX1R upregulation leading to enhanced PVN AVP
signaling. ICV infusion of hypertonic saline in SD rats was performed to mimic
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an increase in CSF sodium concentration to levels observed in HS fed DS rats.
The results showed that ICV infusion of 4 µmol NaCI significantly increased
PVN OX1R and AVP mRNA expression (Figure 3.6) which suggests that
increased CSF sodium concentration, a main phenotype component of DS rats
on a HS diet, may cause PVN OX1R upregulation leading to enhanced AVP
signaling. There have been no studies that have directly determined if orexin
producing neurons are sensitive to changes in osmolality. It has previously
been shown that preopro-orexin mRNA is upregulated In the hypothalamus of
48 hour water deprived rats indicating orexin producing neurons may be
sensitive to changes in osmolality (75). Also the lamina terminalis which is the
location of the primary central osmoreceptors is reported to have efferent
projections to the lateral hypothalamus where orexin producing cell bodies are
located (58, 65) which may explain why orexin neurons would be sensitive to
changes in body fluid osmolality. Interestingly it has been hypothesized that
orexin neurons may be a link between the lamina terminalis sensing of
perturbations in body fluid homeostasis and activating motivation and reward
systems in the mesolimbic system (dopaminergic projection from the ventral
tegmental area to the Nucleus accumbens) to effect salt and water appetite
motivated behavior in order to restore body fluid homeostasis (65).
Finally, since we found DS rats on HS diet displayed increased PVN
mRNA levels of OX1R, OX1R regulates PVN AVP expression, and increased
CSF sodium concentration in HS intake DS rats may cause PVN OX1R
upregulation leading to enhanced AVP signaling, we determined if increased
OX1R activation in the PVN was implicated in HS induced hypertension in DS
rats. Microinjection of The OX1R antagonist SB408124 into the PVN elicited a
significantly greater reduction in MAP in HS DS rats compared to NS DS rats
(Figure 3.8). This result suggests that increased PVN OX1R activation
contributes to the maintenance of HS induced hypertension in DS rats. This is
likely through both increased orexin release into the PVN or increased PVN
OX1R expression since both prepro orexin and OX1R mRNA expression were
upregulated in the PVN of HS DS rats. PVN OX1R blockade also increased
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both SSNA and RSNA in NS and HS rats. Since this experiment was performed
in baroreceptor intact animals this SNA response is likely driven by the arterial
baroreflex mechanism. It should be noted that we did not observe a parallel
reduction in SNA along with the reduction in MAP therefore, it is plausible that
OX1R expressed on magnocellular PVN neurons is responsible for AVP
expression and increased OX1R activation results in greater AVP expression
and possibly release in DS rats on HS diet contributing to the maintenance of
hypertension. Evidence indicates orexin A may bind the OX1R and OX2R on
presynaptic or interneuron glutamatergic PVN neurons and increases
glutamate release to magnocellular PVN neurons (47). Also orexin A may bind
OX1R or OX2R on magnocellular PVN neurons directly and positively
modulates glutamate receptor activity (47). Although the contribution of AVP to
Dahl SSHTN is still controversial, recently it was demonstrated that oral
administration of the dual AVP receptor antagonist RWJ-676070 produced a
transient decrease in MAP in hypertensive DS rats on a HS diet (53)
contributing to evidence that AVP does contribute to Dahl SSHTN. However,
we still cannot ignore the possibility that increased OX1R activation on
parvocellular PVN neurons may be responsible for increased sympathetic tone
and elevated BP in HS DS rats. Performing this same experiment with rats that
have received sino-aortic denervation or severing of the baroreceptor afferents
may clarify whether the mechanism is due to activation of OX1R on
magnocellular or parvocellular neurons. We hypothesize that if increased OX1R
activation on parvocellular PVN neurons is responsible for enhanced neuronal
activity and elevated SNA contributing to hypertension of HS fed DS rats then
OX1R blockade would result in a reduction in both SNA and MAP in sino-aortic
denervated rats.

4.1 Summary and Conclusion
To summarize, the current study showed that a HS diet increased MAP
in DS but not SD rats. DS rats on a HS diet have increased PVN mRNA
expression of Fra1, AVP, orexin precursor, and OX1R indicating the PVN
orexin system may be overactive in hypertensive HS DS rats which display
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enhanced PVN AVP expression. HS intake did not alter PVN mRNA expression
of Fra1, OX1R, or OX2R but increased PVN AVP mRNA expression in HS SD
rats. ICV injection of orexin A in SD rats significantly increased PVN mRNA
expression of AVP. In vitro studies showed activation of OX1R expressed on
hypothalamic neurons mediates AVP expression. ICV infusion of hypertonic
saline in SD rats increased PVN OX1R and AVP mRNA expression. PVN
OX1R blockade significantly reduced MAP in DS rats on a HS diet compared to
DS rats on a NS diet. In conclusion, these findings indicate that increased
OX1R activity in the PVN contributes to enhanced AVP signaling in DS rats on
a HS diet which may contribute to the maintenance of Dahl SSHTN.

4.2 Perspectives
Individuals with hypertension are at an increased risk for cardiovascular
disease, the leading global cause of death. Increased dietary salt intake is a
primary contributor to essential hypertension. Therefore, it is of great interest to
elucidate how salt effects the blood pressure regulatory mechanisms in this salt
sensitive population in order to further treatment possibilities to reduce the
number of deaths caused by cardiovascular diseases. The present study
identifies a novel mechanism were the orexin system may contribute to SSHTN
by enhancing AVP signaling.

4.3 Limitations and Future Studies
There are several limitations that should be acknowledged for this study.
First, PVN brain tissue punch for real-time PCR analysis of mRNA expression
is not exact. Due to the small size of the PVN we acknowledge the possibility
that other surrounding nuclei are included. Additionally, the PVN is composed
of magnocellular AVP producing and pre sympathetic parvocellular neurons.
Therefore, we are unable to determine whether results from real-time PCR
analysis of mRNA expression reflect a specific neuron type. It is also important
to note that animals used for sympathetic nerve recording experiments use an
anaesthetized preparation. This may alter cardiovascular responses to
microinjection of drugs used in this study (46). A major limitation in this study is
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the use of baroreflex intact animals. The baroreflex senses and corrects acute
changes in blood pressure through modulation of SNA. Therefore, responses to
drugs injected into the PVN may be compensated for by reflex modulation of
SNA making interpretation of results difficult. Future studies will include sinoaortic denervated animals in order to remove the baroreflex response. Ongoing
studies in our lab are examining the role of the PVN orexin system in
augmented sympathetic outflow in the Dahl salt sensitive hypertension model.
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Appendix A. Raw Data
Table A.1 Raw data for Conscious Mean Arterial Blood Pressure for Sprague Dawley
and Dahl Salt Sensitive Rats on Normal Salt and High Salt diet.
MAP (mmHg)
SD NS
104
103
104
105
110
106

SD HS
113
110
110
101
108
107

DSNS
114
106
112
113
112
−

DS HS
179
173
150
153
159
140

Table A.2 Raw data for PVN Fra1 mRNA Expression for Sprague Dawley Rats on
Normal Salt and High Salt Diet.
Fra1 mRNA expression normalized to GAPDH mRNA (a.u.)
SD NS

SD HS

0.6

0.66

0.77

2.34

1.76

1.8

0.61

1.02

0.97

−

1.25

−

Table A.3 Raw data for PVN Arginine Vasopressin mRNA Expression for Sprague
Dawley and Dahl Salt Sensitive Rats on Normal Salt and High Salt Diet.
AVP mRNA expression normalized to GAPDH mRNA (a.u.)
SD NS

SD HS

0.61

1.63

1.21

1.61

1.17

1.33

1.18

−

0.97

−

0.83

−
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Table A.4 Raw data for PVN Orexin Receptor 1 mRNA Expression for Sprague
Dawley Rats on Normal Salt and High Salt Diet.
OX1R mRNA expression normalized to GAPDH mRNA (a.u.)
SD NS
SD HS
0.89
1.16
1.00
1.08
1.37
1.29
0.72
1.45
−
1.05
−
1.25

Table A.5 Raw data for PVN Orexin Receptor 2 mRNA Expression for Sprague
Dawley Rats on Normal Salt and High Salt Diet.
OX2R mRNA expression normalized to GAPDH mRNA (a.u.)
SD NS
SD HS
0.75
0.68
0.82
0.8
1.52
0.83
0.89
0.97

Table A.6 Raw data for PVN Fra1 mRNA Expression for Dahl Salt Sensitive Rats on
Normal Salt and High Salt Diet.
Fra1 mRNA expression normalized to GAPDH mRNA (a.u.)
DS NS

DS HS

0.40

3.13

1.22

4.55

0.97

2.11

1.23

1.4

1.13

1.54

0.65

2.15

Table A.7 Raw data for PVN Arginine Vasopressin mRNA Expression for Dahl Salt
Sensitive Rats on Normal Salt and High Salt Diet.
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AVP mRNA Expression Normalized to GAPDH mRNA (a.u.)
DS NS

DS HS

1.12

1.89

1.16

1.75

0.70

4.69

0.82

1.82

1.17

2.09

−

2.37

Table A.8 Raw data for PVN Prepro Orexin mRNA Expression for Dahl Salt Sensitive
Rats on Normal Salt and High Salt Diet.
Prepro Orexin mRNA Expression Normalized to GAPDH mRNA (a.u.)
DS NS
DS HS
2.34
3.16
0.48
4.45
0.16
3.76
1.66
1.52
0.82
1.61
0.94
1.9
0.56
1.42

Table A.9 Raw data for PVN Orexin Receptor 1 mRNA Expression for Dahl Salt
Sensitive Rats on Normal Salt and High Salt Diet.
OX1R mRNA Expression Normalized to GAPDH mRNA (a.u.)
DS NS
DS HS
0.79
1.51
1.00
1.38
1.20
1.21
1.35
2.03
0.61
1.51
0.97
1.62
1.05
1.41
−
0.99
−
0.68

Table A.10 Raw data for PVN Arginine Vasopressin mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and .2 nmol Orexin A in Sprague
Dawley Rats.
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AVP mRNA expression normalized to GAPDH mRNA (a.u.)
Control
.2 nmol Orexin A
1.00
13.41
1.41
4.83
0.59
4.17
0.71
5.98
1.17
1.65
1.35
2.06
0.77
2.73

Table A.11 Raw data for Arginine Vasopressin mRNA Expression Response to 10 nM,
100 nM, 1 µM, and 10 µM Orexin treated Cultured Hypothalamic Neurons.
Control
1.37
0.63
0.83
1.17

AVP mRNA Expression Normalized to GAPDH mRNA (a.u.)
10 nM Orexin
100 nM Orexin
1 µM Orexin
10 µM Orexin
1.76
4.12
6.25
14.22
0.96
1.66
5.02
22.69
1.09
2.56
2.79
8.72
2.28
1.53
5.17
17.26

Table A.12 Raw data for Arginine Vasopressin mRNA Expression Response to 1 µM
Orexin, Orexin co-incubated with Orexin Receptor 1 Antagonist, Orexin co-incubated
with Orexin Receptor 2 Antagonist treated Cultured Hypothalamic Neurons.
Control
1.10
0.90
0.81
1.19

AVP mRNA expression normalized to GAPDH mRNA (a.u.)
1 µM Orexin
Orexin/OX1Ra
Orexin/OX2Ra
1.96
0.65
1.58
2.22
1.11
2.60
3.82
1.73
2.98
2.98
1.32
1.56

Table A.13 Raw data for PVN Orexin Receptor 1 mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague
Dawley Rats.
OX1R mRNA expression normalized to GAPDH mRNA (a.u.)
Control
4 µmol NaCl
1.55
1.23
0.45
1.53
1.08
1.03
0.91
1.52
0.46
1.65
1.23
1.37

56

1.29

1.44

Table A.14 Raw data for PVN Orexin Receptor 2 mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague
Dawley Rats.
OX2R mRNA expression normalized to GAPDH mRNA (a.u.)
Control
4 µmol NaCl
1.13
1.10
0.95
0.60
0.83
1.08
1.08
1.11

Table A.15 Raw data for PVN Arginine Vasopressin mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague
Dawley Rats.
AVP mRNA expression normalized to GAPDH mRNA (a.u.)
Control
4 µmol NaCl
1.00
11.13
1.41
5.73
0.59
−
0.71
1.99
1.17
1.84
1.35
3.57
0.77
−

Table A.16 Raw data for Splanchnic and Renal Sympathetic Nerve Activity response to
Bilateral 30 pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on Normal Salt
diet.

SSNA
Rat

Base
(µV)

Max
(µV)

%Change

Noise
(µV)

Base
(µV)

RSNA
Max
(µV)
%Change

Noise
(µV)

1

0.046

0.057

37.039

0.016

0.018

0.023

45.633

0.008

2
3
4
5
6

0.040
−
−
−
0.022

0.042
−
−
−
0.027

8.653
−
−
−
51.236

0.023
−
−
−
0.013

0.017
−
−
0.015
0.009

0.018
−
−
0.017
0.008

8.264
−
−
21.402
-23.523

0.005
−
−
0.005
0.005
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7
8

0.026
0.022

0.034
0.025

58.240
23.907

0.014
0.010

0.042
0.028

0.05
0.031

29.229
23.859

0.017
0.017

Table A.17 Raw data for Mean Arterial Pressure and Heart Rate response to Bilateral
30 pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on Normal Salt diet.
MAP
Rat
1
2
3
4
5
6
7
8

Base
(mmHg)

Max
(mmHg)

110
122
−
−
102
121
112
106

111
118
−
−
106
103
118
95

HR
Delta
(mmHg)

Base
(mmHg)

1
-4
−
−
4
-18
6
-11

394
363
−
−
378
385
416
386

Max
(mmHg)

Delta
(mmHg)

375
366
−
−
360
364
399
365

-19
3
−
−
-18
-21
-17
-21

Table A.18 Raw data for Splanchnic and Renal Sympathetic Nerve Activity response to
Bilateral 30 pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on High Salt
diet.
SSNA

RSNA
Max
(µV)
%Change

Rat

Base
(µV)

Max
(µV)

%Change

Noise
(µV)

Base
(µV)

Noise
(µV)

1

−

−

−

−

−

−

−

−

2
3
4
5
6
7
8

−
−
0.049
−
0.041
0.050
0.031

−
−
0.066
−
0.048
0.059
0.042

−
−
88.610
−
33.406
26.430
66.841

−
−
0.031
−
0.019
0.017
0.015

0.059
−
0.020
−
0.021
0.030
0.041

0.075
−
0.022
−
0.024
0.031
0.054

36.191
−
15.927
−
33.322
3.222
45.275

0.015
−
0.007
−
0.012
0.016
0.011

Table A.19 Raw data for Mean Arterial Pressure and Heart Rate response to Bilateral 30
pmol SB408124 PVN injections in Dahl Salt Sensitive Rats on High Salt diet.
MAP
Rat
1
2

Base
(mmHg)
−
148

Max
(mmHg)
−
119

HR
Delta
(mmHg)

Base
(mmHg)

−
-29

−
327
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Max
(mmHg)
−
326

Delta
(mmHg)
−
-1

3
4
5
6
7
8

−
152
−
132
144
146

−
128
−
128
133
135

−
-24
−
-4
-11
-11

−
365
−
345
425
346
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−
342
−
348
400
321

−
-23
−
3
-25
-25

Appendix B. Summary Statistics
Table B.1 Average Conscious Mean Arterial Blood Pressure for Sprague Dawley and
Dahl Salt Sensitive Rats on Normal Salt and High Salt diet.
SD NS

SD HS

DS NS

DS HS

6

6

5

6

Mean

105.3

108.2

111.40

159.00

Std. Deviation

2.50

4.07

3.13

14.66

Std. Error of
Mean

1.02

1.66

1.40

5.98

Lower 95% CI of
mean

102.7

103.9

107.5

143.6

Upper 95% CI of
mean

108.0

112.4

115.3

174.4

Number of values

Table B.2 Average PVN Fra1 mRNA Expression for Sprague Dawley and Dahl Salt
Sensitive Rats on Normal Salt and High Salt Diet.
SD NS

SD HS

DS NS

DS HS

6

4

6

6

Mean

1.00

1.46

0.93

2.48

Std. Deviation

0.44

0.75

0.33

1.18

Std. Error of
Mean

0.18

0.37

0.13

0.48

Lower 95% CI of
mean

0.53

0.25

0.58

1.24

Upper 95% CI of
mean

1.46

2.66

1.29

3.72

Number of values
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Table B.3 Average PVN Arginine Vasopressin mRNA Expression for Sprague Dawley
and Dahl Salt Sensitive Rats on Normal Salt and High Salt Diet.
SD NS

SD HS

DS NS

DS HS

6

3

5

6

Mean

1.00

1.52

1.00

2.44

Std. Deviation

0.24

0.16

0.21

1.12

Std. Error of
Mean

0.09

0.09

0.09

0.46

Lower 95% CI of
mean

0.74

1.1

0.73

1.25

Upper 95% CI of
mean

1.25

1.94

1.26

3.62

Number of values

Table B.4 Average PVN Prepro Orexin mRNA Expression for Dahl Salt Sensitive Rats
on Normal Salt and High Salt Diet.
DS NS

DS HS

7

7

Mean

1.00

2.52

Std. Deviation

0.75

1.23

Std. Error of
Mean

0.28

0.46

Lower 95% CI of
mean

0.29

1.41

Upper 95% CI of
mean

1.70

3.69

Number of values

Table B.5 Average PVN Orexin Receptor 1 mRNA Expression for Sprague Dawley
and Dahl Salt Sensitive Rats on Normal Salt and High Salt Diet.
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SD NS

SD HS

DS NS

DS HS

4

6

7

7

Mean

1.00

1.21

1.00

1.52

Std. Deviation

0.27

0.14

0.24

0.25

Std. Error of
Mean

0.13

0.06

0.09

0.09

Lower 95% CI of
mean

0.56

1.06

0.77

1.29

Upper 95% CI of
mean

1.43

1.37

1.22

1.76

Number of values

Table B.6 Average PVN Orexin Receptor 2 mRNA Expression for Sprague Dawley
Rats on Normal Salt and High Salt Diet.
SD NS

SD HS

4

6

Mean

1.00

0.82

Std. Deviation

0.35

0.13

Std. Error of
Mean

0.17

0.05

Lower 95% CI of
mean

0.44

0.68

Upper 95% CI of
mean

1.55

0.97

Number of values

Table B.7 Average PVN Arginine Vasopressin mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and .2 nmol Orexin A in Sprague
Dawley Rats.
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Control

.2 nmol Orexin A

7

7

Mean

1.00

4.97

Std. Deviation
Std. Error of
Mean

0.32

4.02

0.12

1.52

Lower 95% CI of
mean

0.70

1.24

Upper 95% CI of
mean

1.29

8.70

Number of values

Table B.8 Average Arginine Vasopressin mRNA Expression Response to 10 nM, 100
nM, 1 µM, and 10 µM Orexin A treated Cultured Hypothalamic Neurons.
Control

10 nM
Orexin

100 nM
Orexin

1 µM
Orexin

10 µM
Orexin

4

4

4

4

4

Mean

1.00

1.52

2.46

4.80

15.72

Std. Deviation
Std. Error of
Mean

0.33

0.61

1.19

1.45

5.83

0.16

0.30

0.59

0.72

2.91

Lower 95% CI of
mean

0.47

0.54

0.56

2.49

6.43

Upper 95% CI of
mean

1.52

2.5

4.36

7.11

25.01

Number of values

Table B.9 Average Arginine Vasopressin mRNA Expression Response to 1 µM Orexin,
Orexin co-incubated with Orexin Receptor 1 Antagonist, Orexin co-incubated with
Orexin Receptor 2 Antagonist
Control

1 µM
Orexin

Orexin/
OX1Ra

Orexin/
OX2Ra

4

4

4

4

Mean

1.00

2.74

1.20

2.18

Std. Deviation
Std. Error of
Mean

0.17

0.83

0.44

0.72

0.08

0.41

0.22

0.36

0.72

1.41

0.48

1.03

Number of values

Lower 95% CI of
mean
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Upper 95% CI of
mean

1.27

4.07

1.91

3.32

Table B.10 Average PVN Orexin Receptor 1 mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague
Dawley Rats.
Control

4 µmol NaCl

7

7

Mean

1.00

1.40

Std. Deviation
Std. Error of
Mean

0.41

0.21

0.15

0.07

Lower 95% CI of
mean

0.61

1.20

Upper 95% CI of
mean

1.38

1.59

Number of values

Table B.11 Average PVN Orexin Receptor 2 mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague
Dawley Rats.
Control

4 µmol NaCl

4

4

Mean

1.00

0.97

Std. Deviation
Std. Error of
Mean

0.13

0.25

0.06

0.12

Lower 95% CI of
mean

0.78

0.57

Upper 95% CI of
mean

1.21

1.37

Number of values

Table B.12 Average PVN Arginine Vasopressin mRNA Expression Response to
Intracerebroventricular injections of Isotonic saline and 4µmol NaCl in Sprague
Dawley Rats.
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Control

4 µmol NaCl

7

5

Mean

1.00

4.85

Std. Deviation
Std. Error of
Mean

0.32

3.84

0.12

1.71

Lower 95% CI of
mean

0.70

0.08

Upper 95% CI of
mean

1.29

9.62

Number of values

Table B.13 Mean splanchnic sympathetic nerve activity % change from baseline
following PVN microinjection of OX1R antagonist SB408124 in Normal Salt and High
Salt Dahl Salt Sensitive rats.
SB408124
DS NS

SB408124
DS HS

5

5

35.82

48.20

20.14

28.19

9.00

12.61

Lower 95% CI
of mean

10.81

13.19

Upper 95% CI
of mean

60.82

83.21

Number of
values
Mean
Std. Deviation
Std. Error of
Mean

Table B.14 Mean renal sympathetic nerve activity % change from baseline following
PVN microinjection of OX1R antagonist SB408124 in Normal Salt and High Salt Dahl
Salt Sensitive rats.

Number of
values
Mean
Std. Deviation
Std. Error of
Mean

SB408124
DS NS

SB408124
DS HS

6

5

17.48

26.79

23.46

16.93

9.57

7.57
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Lower 95% CI
of mean

-7.14

5.76

Upper 95% CI
of mean

42.10

47.81

Table B.15 Mean change from baseline for mean arterial pressure (mmHg) following
PVN microinjection of OX1R antagonist SB408124 in Normal Salt and High Salt Dahl
Salt Sensitive rats.
SB408124
DS NS

SB408124
DS HS

6

5

-3.66

-15.80

9.30

10.33

3.80

4.62

Lower 95% CI
of mean

-13.44

-28.63

Upper 95% CI
of mean

6.10

-2.97

Number of
values
Mean
Std. Deviation
Std. Error of
Mean

Table B.16 Mean change from baseline for heart rate (beats/minute) following PVN
microinjection of OX1R antagonist SB408124 in Normal Salt and High Salt Dahl Salt
Sensitive rats.
SB408124
DS NS

SB408124
DS HS

6

5

-15.50

-14.20

9.20

13.97

3.75

6.24

Lower 95% CI
of mean

-25.16

-31.55

Upper 95% CI
of mean

-5.84

3.14

Number of
values
Mean
Std. Deviation
Std. Error of
Mean

Table B.17 Unpaired t-test comparing MAP and PVN mRNA expression of Fra1,
Arginine Vasopressin, Orexin Receptor 1, and Orexin Receptor 2 between Normal Salt
and High Salt Sprague Dawley rats.
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Group 1
vs.
Group 2

Fra1
mRNA

AVP
mRNA

OX1R
mRNA

OX2R
mRNA

MAP

SD NS

SD NS

SD NS

SD NS

SD NS

vs

vs

vs

vs

vs

SD HS

SD HS

SD HS

SD HS

SD HS

0.2573

0.0121

0.1411

0.3033

0.177

ns

*

ns

ns

ns

Twotailed

Twotailed

Twotailed

Twotailed

Twotailed

t=1.220
df=8

t=3.357
df=7

t=1.633
df=8

t=1.100
df=8

t=1.452
df=10

Unpaired t test
P value
P value summary
One- or two-tailed P
value?
t, df

Table B.18 Unpaired t-test comparing MAP PVN mRNA expression of Fra1, Arginine
Vasopressin, Prepro Orexin, and Orexin Receptor 1 between Normal Salt and High Salt
Dahl Salt Sensitive Rats.

Group 1
vs.
Group 2

Fra1
mRNA

AVP
mRNA

Prepro
Orexin
mRNA

OX1R
mRNA

MAP

DS NS

DS NS

DS NS

DS NS

DS NS

vs

vs

vs

vs

vs

DS HS

DS HS

DS HS

DS HS

DS HS

0.0117

0.0210

0.0148

0.0019

<0.0001

*

*

*

**

****

Twotailed

Twotailed

Twotailed

Twotailed

Twotailed

t=3.077
df=10

t=2.791
df=9

t=2.842
df=12

t=3.959
df=12

t=7.068
df=9

Unpaired t test
P value
P value summary
One- or two-tailed P
value?
t, df

Table B.19 Unpaired t-test comparing PVN Arginine Vasopressin mRNA Expression
Response to Intracerebroventricular injections of control vs. 2 nmol Orexin A in
Sprague Dawley Rats.
67

AVP mRNA
Control

Group 1

vs
.2 nmol Orexin
A

vs.
Group 2
Unpaired t test

0.0232

P value

*

P value summary
One- or two-tailed P
value?

Two-tailed
t=2.602 df=12

t, df

Table B.20 Unpaired t-test comparing Arginine Vasopressin mRNA Expression
Response to Control vs. 10nM orexin, 100 nM orexin, 1 µM Orexin, and 10 µM Orexin
treatment in cultured hypothalamic neurons.

Group 1
vs.
Group 2

AVP
mRNA

AVP
mRNA

AVP
mRNA

AVP
mRNA

Control

Control

Control

Control

vs

vs

vs

vs

10 nM
Orexin

100 nM
Orexin

1 µM
Orexin

10 µM
Orexin

0.1855

0.0555

0.0022

0.0024

ns

ns

**

**

Twotailed

Twotailed

Twotailed

Twotailed

t=1.495
df=6

t=2.370
df=6

t=5.111
df=6

t=5.037
df=6

Unpaired t test
P value
P value summary
One- or two-tailed P
value?
t, df

Table B.21 One way anova with post hoc Newman-Keuls test comparing Arginine
Vasopressin mRNA Expression Response between control, 1 µM Orexin, Orexin coincubated with Orexin Receptor 1 Antagonist, Orexin co-incubated with Orexin
Receptor 2 Antagonist treated hypothalamic neurons.
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ANOVA summary
F

7.458

P value

0.0044

R square

0.6509

ANOVA table
Treatment (between
columns)
Residual (within
columns)
Total
Newman-Keuls

SS

DF

MS

8.132

3

2.711

4.362

12

0.3635

12.49

15

Mean Diff.

Significant ?

Summary

-1.745

Yes

**

-1.18

Yes

*

-0.202

No

ns

-1.543

Yes

**

-0.977

Yes

*

-0.565

No

ns

Control vs 1 µM
Orexin
Control vs Orexin/
OX2Ra
Control vs Orexin/
OX1Ra
Orexin/OX1Ra vs 1
µM Orexin
Orexin/OX1Ra vs
Orexin/OX2Ra
Orexin/OX2Ra vs 1
µM Orexin

Table B.22 Unpaired t-test comparing Orexin Receptor 1, Orexin Receptor 2, and Arginine
Vasopressin mRNA response between intracerebroventricular injections of isotonic saline
vs. 4 µmol NaCl in Sprague Dawley rats.

Group 1
vs.
Group 2

OX1R
mRNA

OX2R
mRNA

AVP mRNA

Control

Control

Control

vs

vs

vs

4 µmol NaCl

4 µmol NaCl

4 µmol NaCl

0.0433

0.87

0.0226

*

ns

*

Two-tailed

Two-tailed

Two-tailed

t=2.259 df=12

t=0.1663, df=6

t=2.694 df=10

Unpaired t test
P value
P value summary
One- or two-tailed P
value?
t, df
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Table B.23 Unpaired t-test comparing splanchnic sympathetic nerve activity % change,
renal sympathetic nerve activity % change, mean arterial pressure, and heart rate change
from baseline following PVN microinjection of OX1R antagonist SB408124 in Normal
Salt and High Salt Dahl Salt Sensitive rats.

Group 1
vs.
Group 2

SSNA

RSNA

MAP

HR

SB408124
DS NS

SB408124
DS NS

SB408124
DS NS

SB408124
DS NS

vs

vs

vs

vs

SB408124
DS HS

SB408124
DS HS

SB408124
DS HS

SB408124
DS HS

0.2236

0.2395

0.0353

0.4284

ns

ns

*

ns

One-tailed

One-tailed

One-tailed

One-tailed

t=0.7992
df=8

t=0.7387
df=9

t=2.050
df=9

t=0.1856
df=9

Unpaired t test
P value
P value summary
One- or twotailed P value?
t, df
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